Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

NCT04864834 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

485

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL: SOK583A1 (40 mg/mL)
BIOLOGICAL: Eylea EU (40 mg/mL)

Sponsor

Sandoz